Omnicom Public Relations Group Forms Strategic Alliance with LaVoieHealthScience

NEW YORK, January 7, 2020 Omnicom Public Relations Group (OPRG), a division of Omnicom Group (NYSE: OMC) announced today a strategic alliance with LaVoieHealthScience (LHS) to bring global clients a broader set of integrated health and science experienced teams. The alliance combines the scale of OPRG with LHS’s capabilities in strategic communications, including investor relations and financial communications as well as expertise in development-stage health and science innovation. The agencies will share client referrals and marketing resources as well as new business development opportunities.

OPRG’s combined agency health verticals create an offering called OPRG Health, consisting of 1,200 health consultants across 14 agencies in more than 100 countries globally. As the health landscape becomes increasingly complex and with disruption through innovation happening faster than ever before, OPRG Health has been organized to deliver best in class teams of consultants and specialists that can scale quickly worldwide to deliver solutions for any business-defining moment.

“The biotech and life science sector has been key in the year-on-year growth within OPRG’s health portfolio,” said Paul George, Global Business Leader, Health at Omnicom Public Relations Group. “With LaVoieHealthScience’s added expertise, we will deliver to clients a full suite of integrated communications, investor relations, change management, advocacy, policy and marketing services from Series A through IPO, product commercialization and beyond.”

“At LaVoieHealthScience, we help health and science companies launch, emerging companies develop, and established companies grow. Our year-on-year growth is being driven by the rapid pace of innovation in the health and science fields fueled by record-breaking annual U.S. healthcare funding levels, market valuations and continued marketing approvals of 48 new medicines in 2019 in the US alone. Providing clients with end-to-end capabilities in global markets is imperative in our agency’s strategy and client-service plan,” said founder and CEO, Donna L. LaVoie, LaVoieHealthScience. “We’ve been working together for a year now and formalizing the alliance seemed fitting, given our combined track record of success.

About Omnicon Public Relations Group
Omnicon Public Relations Group is a global collective of three of the top global public relations agencies worldwide and specialist agencies in areas including public affairs, marketing to women, global health strategy and corporate social responsibility. It encompasses more than 6,300 public relations professionals in more than 370 offices worldwide who provide their expertise to companies, government agencies, NGOs and nonprofits across a wide range of industries. Omnicom Public Relations Group delivers for clients through a relentless focus on talent, continuous pursuit of innovation and a culture steeped in collaboration. Omnicom Public Relations Group is part of the DAS Group of Companies, a division of Omnicom Group Inc. (NYSE: OMC) that includes more than 200 companies in a wide range of marketing disciplines including advertising, public relations, healthcare, customer relationship management, events,
promotional marketing, branding and research.

About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides strategic consulting, public relations and investor relations to build recognition and increase sales and value for health science innovations and has two trademarked methodologies for its strategic communications advisory services. The agency has received over 30 awards in recognition of the work done by its strategic thinkers for health and science industry-leading clients. LHS was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, as well as ranked on the O’Dwyer’s list of 2019 Healthcare Public Relations Firms and Boston Business Journal’s top PR Agencies in Massachusetts.

 

Contacts

Agency and Media:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

LaVoieHealthScience Reports on First Thought Leadership Panel, An Unvarnished Look at JPM Week

Industry Veterans Bullish on 2020, Recommend Company Executives Have a Clear Plan for ROI at #JPMWeek 2020 and Suggest Other Venues for Future Industry Gatherings

Link to Full Audio Recording Now Available

BOSTON, January 2, 2020LaVoieHealthScience (LHS), a leading strategic communications firm dedicated to advancing health and science innovation, reported today on the agency’s first annual panel held on December 19 in Cambridge, Massachusetts, entitled, An Unvarnished Look at JPM Week 2020. Today, JPM Week brings together the largest group of industry, private and public company investors as well as business partners in one place to discuss the business of science and innovation, with a keen eye toward improving lives of patients and caregivers. The focus of the panel was to discuss the unpublished truths of attending and making the most of the yearly conference, increasing return on investment.

“Despite the investor, business development and licensing focus of JPM Week (also known as Biotech Week), the true winners should be patients, and JPM Week is often the first stop for healthcare pioneers who are striving to bring lifesaving medical innovation to the marketplace,” said Donna L. LaVoie. “Our panelists brought tremendous insight into this process, based on years of experience in attending JPM Week with a focus on critical fundraising, licensing, news flow and meeting colleagues.”Moderated by LHS CEO, Donna L. LaVoie, panelists included Chris Garabedian, CEO of Xontogeny LLC and Portfolio Manager, Venture for Perceptive Advisors; Daphne Zohar, CEO and founder, PureTech Health; Milenko Cicmil, Vice President of Global Innovation & Partnering at Ipsen Biopharmaceuticals; and Jon Civitarese, Managing Director, Investment Banking, SVB Leerink LLC. The panel discussion covered JPMorgan history, decision tree for attending JPM Week by type of company, various venues – events, luncheons, cocktail parties, one-on-one meetings, meeting-making tools, how to best prepare, highlights and low lights of 2019, as well as 2020 predictions.

Panelists anticipated a robust 2020 financing market for healthcare and biotech companies. This is evidenced by the record increases of the 38 VC-backed “unicorns,” currently valued at more than $70 Billion, as well as a number of mega-round private financings.

Donna L. LaVoie commented, “Our panelists were bullish on 2020. As reported recently in BioWorld, the biopharma sector scored approval of 48 new medicines in 2019, an above average number. Our panelists indicated that this bodes for a strong follow-on offering and IPO market in first half of 2020.”

Panelists brought top tips and advice to company executives as they plan for JPM Week in 2020 and beyond:

  • If you have important clinical or technical updates, JPM Week is the marquee venue at the start of the year to update potential partners and investors. Your news flow here sets the stage for the rest of the year.
  • Determine in advance who you want to meet with and why during JPM Week. Do it methodically – and be sure to follow up, post conference.
    • Avoid superficial meetings with targets that are not aligned with your company’s goals that won’t go anywhere post JPM.
  • Target investors, partners and media that you don’t normally get to meet with. Avoid the temptation of meeting with local colleagues, as this can be done anytime during the year.
  • Get invited to the pharmaceutical partner events, which have numerous investors and key executives in attendance. And determine in advance who you’d like to meet. For a full list of events, visit BIO Compass.
  • When meeting with pharmaceutical partners, limit your entourage. Focus on bringing key content contributors such as chief medical or science officer, other relevant scientific personnel.
  • Bring some humanity to San Francisco. There are many organizations within the biotech/life science ecosystem such as Life Science Cares and others who are working to address issues of poverty and homelessness in their communities. Give them your support.
  • Focus on quality versus quality. Fill two days instead of four.
  • Tell your story simply – utilize a company fact sheet, The LHS Fifteen Slide Presentation®; avoid the long corporate deck.
  • Have a backup – bring electronic and paper copy of your fact sheet or presentation. And use whatever is most appropriate for the venue.
  • Maintain confidentiality on airplanes and in taxis and ride shares – you are not alone.

Panelists encouraged new thinking around this yearly industry event, given the high cost of hotels, travel, meeting rooms, etc., and suggested Massachusetts as a natural future venue for meetings, given the proximity to investors, academic centers, pharma and biotech companies, and the media.

“Our panelists are calling for more careful use of time and better efficiency, no matter the size of company attending JPM Week,” said Donna L. LaVoie. “The value of this meeting will more than likely shift as new thinking evolves around how best to kick off the new year, meet investors, media and partners and achieve business goals.”

Link to Full Event Audio Recording

About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, ranked on the O’Dwyer’s list of 2019 Healthcare Public Relations Firms, PR Week’s list of 2019 Top Agencies and Boston Business Journal’s list of Largest Public Relations Firms in Massachusetts.

 

Contacts

Agency and Media:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

LaVoieHealthScience Executive Panel Presents “An Unvarnished Look at J.P. Morgan Week 2020”

Distinguished Panel to Provide Health Executives with Valuable Insights into JPM Week and Ways to Maximize Your Presence in San Francisco this January

BOSTON — LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced it is hosting a breakfast panel featuring senior health and investment executives titled, An Unvarnished Look at J.P. Morgan Week 2020, from 8:30 to 10:30 a.m. on Thursday, Dec. 19, 2019 at the Royal Sonesta in Cambridge, MA.

The panel is designed for CXOs, senior BD and communications executives at health companies to prepare them for and provide insights into the collection of biotech conferences held during the week of the J.P. Morgan 38th Annual Healthcare Conference, Jan. 12-16 in San Francisco. Panelists will examine the value of attending JPM Week, sharing in-depth insights based on personal experience.

Moderated by Donna LaVoie, President and CEO of LHS, the panel includes industry leaders:

  • Chris Garabedian, Chairman and CEO, Xontogeny, and Portfolio Manager, Venture for Perceptive Advisors
  • Daphne Zohar, Founder and CEO, PureTech Health
  • Milenko Cicmil, VP, Global Head of External Innovation & Partnering, Ipsen
  • Jon Civitarese, Managing Director, Investment Banking, SVB Leerink LLC

Topics to be discussed include:

  • The evolution of the J.P. Morgan Healthcare Conference
  • JPM Week 101: Who goes and why?
  • Is attending worth your company’s time and expense?
  • What is the value for large pharma companies versus smaller, private companies?
  • What is the best way to leverage JPM Week to tell an investable story that builds value?
  • Is it a good time to announce news? What kind of news matters?

Registration, breakfast and networking begin at 8:30 a.m., the panel discussion begins at 9 a.m. and a Q&A session will follow from 10 to 10:30 a.m.

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, ranked on the O’Dwyer’s list of 2019 Healthcare Public Relations Firms, PR Week’s list of 2019 Top Agencies and Boston Business Journal’s list of Largest Public Relations Firms in Massachusetts.

Contacts

Agency and Media:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

LaVoieHealthScience Looks to the Future, Promotes Sharon Correia and Ella Deych

BOSTON/NEW YORK — August 13, 2019 — LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced the promotion of two of the agency’s senior-level employees. Sharon Correia, who has been with LHS full-time since 2016, will serve as Executive Vice President, Integrated Communications and Chief Strategy Officer. Ella Deych, who joined LHS in 2015 as the agency’s first executive overseeing finance and operations, is now Vice President, Finance and Chief Operations Officer.

Sharon is an industry veteran who boasts more than twenty years of experience in health and science communications. She joined LHS in 2016 as Vice President, Integrated Communications after previously serving the agency as a senior consultant since 2010, whilst ramping up on an orphan drug communication commercialization program for Pfizer. Prior to making a full-time move to LHS, she held the role of Senior Director, Corporate Communications at Navidea Biopharmaceuticals as well as other communications and PR roles at emerging biopharmaceutical companies.

“Over the last several years, Sharon has grown with the agency — evolving her position from a hands-on executor to a senior executive capable of digging in while providing overall strategic direction on our accounts,” stated Donna LaVoie, President and CEO. “As Executive Vice President, Integrated Communications and Chief Strategy Officer, Sharon will work with me and our senior leadership team to drive strategic direction on existing and new client business.”

In 2015, Ella joined LHS from Racepoint Global, where she most recently served as the firm’s Finance Manager. Since starting at LHS as the agency’s Director of Finance and Operations, Ella has held several titles of increasing responsibility. “She has shown yearly growth and progression and has long been an important member of the senior leadership team,” said LaVoie. 

As the Vice President, Finance and Chief Operations Officer, Ella will be the senior executive tasked with overseeing the day-to-day administration and operational functions of the agency.

With new clients, new hires and the promotions of Sharon and Ella, our agency is seeing significant growth in our eighteenth year as a firm. I look forward to the future with my incredible team,” concluded LaVoie.

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, ranked on the  O’Dwyer’s list of 2019 Healthcare Public Relations Firms, PR Week’s list of 2019 Top Agencies and Boston Business Journal’s list of Largest Public Relations Firms in Massachusetts.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.co

LaVoieHealthScience Signs Eight New Clients in 1H:2019 Makes Additional Hires and Launches IR-Focused Thought Leadership Series

BOSTON & NEW YORK – July 29, 2019 – LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced eight new client partnerships, additional hires and the launch of an investor relations thought leadership series. This builds on the agency’s foundational accounts with winning public and private global health companies and industry organizations.

New clients represent both public and privately held pre-commercial and commercial companies in key areas of industry growth, including cell, stem and gene therapy, CNS, rare disease, oncology, cardiovascular and retinopathy, as well as life science service providers.

LHS also began working in partnership with LeadingBiotech, a KNECT365 Informa business. The two firms will work in partnership to communicate and co-promote an exclusive event series bringing together senior-level biopharma leaders through off-the-record collaboration and dialogue meetings.

LHS’s work highlights the strength of our people and our collaborations and the importance of LHS’s proprietary methodologies including the LHS Immersion® and Blueprint plan, which forms the basis of core strategic communications and marketing programming.

“It’s all about our people and our clients – we keep them close. In our eighteenth year as a firm, I could not be more excited about our industry and its role in advancing health innovation,” said Donna L. LaVoie, President and CEO. “Working with unique and innovative clients and helping them tell their stories with a purpose, while solving complex communications challenges builds value and makes it worthwhile.”

To support a growing client roster, LHS has added Emmie Twombly as a Media Relations Specialist, Jessica Morris and Hannah Mongeon, both Account Coordinators and Harriet Ullman as a Senior Consultant, Product Communications. Emmie brings to the team media and public relations experience in the healthcare and financial sectors, placing print, online and broadcast stories. In addition to her strong strategic communications and writing background, she brings a passion for empowering women and developing thought leadership pieces. Jessica Morris and Hannah Mongeon came to LHS as part of the Mass Life Science Center Internship Challenge and bring excellent support to our teams.

Harriet Ullman brings 25 plus years of business and communications experience in the pharmaceutical industry and business consulting and was previously Vice President in the Healthcare Practice at Ogilvy PR/Feinstein Kean Healthcare. She provides clients with integrated communications support – from product communications, advocacy relationship management and media relations to strategic corporate positioning, branding and issues management.

In addition to expanding its strategic communications team this month, LHS also debuted the LHS IRalert, a thought leadership series aimed at providing updates on key IR trends for life science companies. The first alert informs life science companies on what they need to know about MiFID II.

AboutLaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, as well as ranked on the O’Dwyer’s list of 2018 Healthcare Public Relations Firms.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.co

LaVoieHealthScience Honored with Bell Ringer Awards in Both Investor Relations and Executive Thought Leadership Categories

BOSTON — June 7, 2019 — LaVoieHealthScience (LHS), an integrated public and investor relations agency focused on advancing health and science innovations, today announced it is the recipient of two 2019 Bell Ringer Awards. The agency was awarded a Bronze Bell for Investor/Financial Relations Campaign for its work with client Newron Pharmaceuticals SpA (SWX: NWRN) and a Merit Award for Executive Thought Leadership Campaign for client Xontogeny LLC.

LHS was recognized for its investor relations work on Newron’s 2018 Research and Development (R&D) Day held this past October in New York City. An Italian-based company with a primarily European investor base, Newron sought to expand its investor presence in the United States. The LHS team crafted a comprehensive campaign to expand U.S. and global investor visibility for Newron, including creation of a scientific and investor-oriented R&D Day, strategic investor outreach and development of a U.S.-centric marketing strategy to secure both an in-person and global online audience for the event.

For client Xontogeny, LHS created a strategic executive thought leadership campaign for Chairman and CEO Chris Garabedian – an industry pioneer with more than 25 years of experience guiding and building biopharma companies to ensure development success. Building on his position as an industry leader, the campaign included an exclusive webinar series with Xconomy, strategic thought leadership placements on key conference panels and placements in business, financial and industry media outlets – totaling 16 unique pieces of coverage.

“It’s an honor to be acknowledged again this year by the PR Club of New England. This is a well-deserved recognition for the talented integrated investor and public relations team at LHS,” stated Donna L. LaVoie, President and CEO.

The Bell Ringer Awards are held annually by the PR Club of New England and celebrate the outstanding achievements of the region’s public relations and marketing professionals.

In 2018, LHS was awarded the Silver Bell Ringer Award by the PR Club of New England in the Investor/Financial Relations Campaign category. The agency has won a total of 12 Bell Ringer Awards since 2009.

AboutLaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

Two LaVoieHealthScience Workshops at 2019 BIO International Convention to Highlight Strategies for Communicating with Investors, Media and Partners

Faculty includes Industry Veterans, Dr. Mark Monane, Angus McQuilken and LaVoieHealthScience Consultants

BOSTON – April 11, 2019 – This year at the 2019 BIO International Convention, to be held in Philadelphia, PA, a new workshop will feature faculty members from Monane Group Clinical Consulting LLC, international law firm McDermott Will & Emery  and LaVoieHealthScience.

This pre-conference half-day workshop session, titled Building Value for Your Assets: Communicating with Investors and Partners, takes place Sunday, June 2, 2019 from 1:00-5:00 PM. Convention registration is not needed to attend this workshop, but advanced registration is required. Register here

This interactive workshop is for mid-to-senior executives of biotechnology, pharma, medical, digital health, medical device and diagnostic companies. Learn from case studies and come away with tangible deliverables designed to jumpstart your communications program around an investable story that builds value for your assets.

Presenters include Dr. Mark Monane, Principal and Chief Medical Officer of Monane Group Clinical Consulting LLC, and Angus McQuilken, Business Development Manager, Life Sciences at McDermott Will & Emery.

As an experienced medical strategist as well as former sellside analyst and chief medical officer, Dr. Monane offers an essential Wall Street insight on story-telling that resonates, while McQuilken, former Vice President for Communications & Marketing for the Massachusetts Life Sciences Center, a state-funded life science investment agency, provides media, communications and marketing insights from working with early and mid-stage life sciences companies.

Senior consultants at LaVoieHealthScience including Donna L. LaVoie, President & CEO, Sharon Correia, SVP, Integrated Communications and Paul Sagan, AVP, Investor Relations & Corporate Communications, provide practical experience from the combined 50+ years of experience in life sciences investor, partner and media case study work.

“It’s an honor to provide key learnings to life science companies from around the globe at this pre-conference workshop with my distinguished faculty,” stated Donna L. LaVoie.

During the 2019 BIO International Convention, Donna L. LaVoie will also present the LHS Fifteen Slide Presentation® workshop on Monday, June 3, 2019 at 1:00 PM. This workshop is designed help companies tell their company story in just fifteen slides. Audience members at this session will have the unique opportunity to share their elevator pitches and receive live feedback.

About 2019 BIO International Convention

The 2019 BIO International Convention offers access to the BIO Business Forum, 3,500 companies in BIO One-on-One Partnering™, keynotes, BIO evening events, premium education sessions and 19+ session tracks.

AboutLaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

LHS Enters NYC Market with Hiring of Investor Relations Health & Science Industry Expert Sharon Choe to Fuel Demand for Integrated Services Model

Firm Names IR Practice LaVoieHealthScience-IR (LHS-IR)

BOSTON – March 1, 2019 – LaVoieHealthScience (LHS), an integrated public and investor relations agency focused on advancing health and science innovations, today announced the hiring of Sharon Choe as Senior Vice President, Investor Relations & Business Development and the naming of its IR practice, LHS-IR. LHS-IR will focus on investor relations counsel, access and financial communications and Key Opinion Leader/Investor events, while the PR practice will continue to lead strategic communications engagements focused on story-telling including media and social media programming, medical/scientific communications, advocacy, spokesperson training and messaging. The firm expands its ability to provide integrated services to health and science clients worldwide.

This addition expands the firm’s presence from its strong roots in Boston/Cambridge, Massachusetts to the NYC financial market to fuel client demand for LHS’ integrated services model. Recent client wins with publicly-traded, global companies seeking US representation has accelerated LHS’ need to expand its talent. LHS’ integrated service model experienced 19 percent revenue growth over the previous fiscal year. In 2018, the firm added additional senior talent, including Doug Russell as Sr. VP & GM and Paul Sagan, AVP, Investor Relations and the promotion of Lisa DeScenza, VP, Integrated Communications.

Sharon joins the LHS team from The Ruth Group in NYC, where she has served as Senior Vice President since November 2015 until recently. Prior to her time at The Ruth Group, Sharon spent four years as Managing Director at Life Sci Advisors. As an industry veteran with extensive experience in life sciences, Sharon will use her expertise and network to expand business development for LHS, deploy best practices, hire talent and provide additional investor connections for LHS clients. Sharon will report to LHS President & CEO, Donna L. LaVoie and will be part of the Senior Leadership Team.

“We are proud to attract Sharon to our unique team of experts. Sharon will work with me and our senior team to scale the investor relations practice and build infrastructure. We will leverage our strong base of integrated public relations business, supporting leading innovators in our sector to extend our reach to the New York City financial market,” stated LaVoie.

Sharon also brings valuable experience on the buy side as a healthcare & biotech analyst at firms including UBS Asset Management, Credit Suisse Asset Management and BAM Capital LLC. “Sharon knows her way around the biotech community and Wall Street and I am certain she will play an important role with the rest of our team as we continue to add to our bench of talented specialized thinkers and executors in health and science communication,” concluded LaVoie.

“I am extremely excited by the opportunity to help lead LaVoieHealthScience’s strategic integration strategy of building a dedicated Investor Relations team to support the company’s award-winning public relations platform,” said Sharon. “I look forward to working with LHS’ talented team to advance the firm through its next phase of growth.”

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received 50+ award in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. The firm is known for its two trademarked methodologies for its messaging/positioning program (The LHS Immersion®) as well as how to tell your company story in 15 slides (The LHS Fifteen Slide Presentation®).

LaVoieHealthScience represents leaders such as, AC Immune SA, Biotechnology Industry Organization, Carmell Therapeutics, Genosco, Landos Biopharma, LEO Science & Tech Hub, NewLink Genetics, Newron Pharmaceuticals SpA, Origenis GmbH, PathMaker Neurosystems, Propanc BioPharma, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Torreya Partners, Triumvira Immunologics, Xontogeny LLC, and other emerging health and science companies.

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing

kgallagher@lavoiehealthscience.com
617-374-8800 x109

Business Development Contact:
Sharon Choe
Senior Vice President,
Investor Relations & Business Development

schoe@lavoiehealthscience.com
857-241-7393

SIRION Biotech Names LaVoieHealthScience as Strategic Communications Agency of Record

SIRION Biotech Plans Path for US Market Expansion

Boston, MA & Martinsried, Germany – November 4, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that Europe’s leading gene therapy engineer of viral vectors, SIRION Biotech GmbH, is now a client of LaVoieHealthScience.  LHS provides strategic communications programming and corporate development expertise to SIRION Biotech, helping to connect SIRION Biotech to relevant stakeholders in the U.S. life science ecosystem.  This is particularly important as SIRION Biotech plans its expansion into the U.S. market with its new Cambridge, MA site beginning January 2019.

SIRION Biotech has been engaged in research and licensing collaborations with 3 leading US biotechs in the gene therapy field since 2015. The earliest project was assisted by LaVoieHealthScience beginning in 2014, when the Germany based company with deep scientific roots in gene expression was seeking U.S. partnerships with clinical-stage gene therapy companies in order to expedite their R&D efforts.  Partnering together, LaVoieHealthScience and SIRION Biotech built its US profile, visibility and outreach efforts. 

“Partnering with LaVoieHealthScience helped us unleash our potential as a business to business provider of custom engineered viral vectors for industrial and academic research and development,” said Chief Operating Officer and Executive Director, Dieter Lingelbach.  Our planned expansion into the US market will be a strategic imperative for SIRION Biotech and we are delighted to continue working with LaVoieHealthScience as we chart our course forward.”

“We are fortunate to continue working with SIRION Biotech as Europe’s leader in the field on its next stage of growth and continue our successful partnership together, said Donna L. LaVoie, President & CEO of LaVoieHealthScience.  Dieter and founder, Chief Technology Officer, Dr. Christian Thirion have great vision to enable gene therapy and gene editing companies become more successful with the right clinical grade vector technology that will scale through manufacturing.”

About LaVoieHealthScience

LaVoieHealthScience provides public relations, investor relations, marketing and digital communications to build recognition and value for health science innovators. The agency has received more than 30 awards during the past seven years in recognition of the work it has done for its industry-leading clients and was recently inducted into the 2018 Inc. 5000 Hall of Fame list of Fastest Growing Private Companies. LaVoieHealthScience represents public and privately-held leaders such as BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies. For more information, please visit: https://lavoiehealthscience.com/

 

About SIRION Biotech GmbH

SIRION Biotech provides custom engineering and manufacturing services of viral vectors for the life sciences and industry. Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOSTTM transduction reagent is actively used to improve hematopoitec cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.

www.sirion-biotech.com

 

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing

kgallagher@lavoiehealthscience.com
617-374-8800 x109

 

LHS Partners with LSX World Congress USA

 
 
The LSX World Congress brought life science executives together here in Boston for strategy, investment, and partnering opportunities. As an event partner, LHS is thrilled to have participated in several key event tracks, including IPO Bootcamp, the Big Data Driven Innovation panel and two Fireside Chats.  
Fireside chat with Donna LaVoie and Pavan Cheruvu

As co-host of the IPO Bootcamp, held on Tuesday, October 9, at the Union Club in Boston, LHS was thrilled to be the investor relations consultant for executives looking for best practices for a successful IPO. The day began with an opening address from David Ethridge of PwC on the current state of the IPO market, and continued with an overview of the healthcare ECM from Jordan Saxe, Senior Managing Director at Nasdaq. A roundtable discussion on determining and defining an IPO strategy followed, with leaders from PwC, Nasdaq, Covington & Burling, Oppenheimer & Co, and LavoieHealthScience offering insights.

We are also grateful to have had SVP and General Manager, Doug Russell, moderate the LSX panel on Big Data Driven Innovation on Thursday, October 11.  Pharma and life science executives discussed how they’re harnessing the power of big data to advance drug discovery and development. Panelists included Leila Pirhaji, Founder and CEO of ReviveMed, Josh Mandel-Brehm, CEO of Camp4 Therapeutics, Gini Desphande, Founder and CEO of NuMedii, Alex de Winter, Managing Director at GE Ventures, and Janna Hutz, Senior Director, Head of Human Biology & Data Science at Eisai.  Doug led a lively discussion on the topic, with a focus on the future promise of big data in life science innovation.

Big Data Panel with Doug Russell
Fireside Chat with Paul Sagan and Brian Pereira

CEO Donna LaVoie and Paul Sagan, AVP, Investor Relations and Communications, also conducted fireside chats with pharma executives at the LSX World Congress.  Pavan Cheruvu, the CEO of Axovant, spoke with Donna LaVoie on the details of building a successful gene therapy portfolio.  Later in the evening, Paul Sagan and Brian Pereira, the CEO of Visterra, discussed the anatomy of a clinical-stage acquisition.  Pereira, whose company was recently acquired by the Pharmaceutical Co., Ltd of Japan, offered a timely and relevant perspective on the topic. 

The two day conference offered many interesting and engaging panels as well as great networking opportunities. LHS is happy to have partnered with LSX this year for a successful World Congress.